MAESTrO: Merck receives approval of Zepatier (elbasvir/grazoprevir) in Canada for the treatment of chronic hepatitis C for patients with genotype 1, 3, or 4 infection following priority review

Posted by Michael Wonder on 04 Feb 2016

Merck receives approval of Zepatier (elbasvir/grazoprevir) in Canada for the treatment of chronic hepatitis C for patients with genotype 1, 3, or 4 infection following priority review

3 February 2016 - Zepatier achieves high cure rates (SVR12) of 95-98% in a broad range of patients with chronic hepatitis C infection, including those with compensated cirrhosis, renal impairment of any degree and HIV-1/HCV co-infection.

For more details, go to: http://www.merck.ca/Assets/News/Merck%20Canada%20Press%20Release%20-%20ZEPATIER%20Launch%20-%20FINAL%20-%20Feb%203%202016%20-%20EN.pdf

Posted by:

Michael Wonder

Posted in:

Outcome , Combination product , Canada , Accelerated approval , Hepatitis C